These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36036236)

  • 1. Identification of apple cultivars hypoallergenic for birch pollen-allergic individuals by a multidisciplinary in vitro and in vivo approach.
    Strobl MR; Vollmann U; Eckl-Dorna J; Radakovics A; Ibl V; Schnurer M; Brenner M; Dermendjiev G; Weckwerth W; Neumüller M; Frommlet F; Demir H; Bublin M; Müller C; Bohle B
    Clin Transl Allergy; 2022 Aug; 12(8):e12186. PubMed ID: 36036236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allergen-specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy.
    Nothegger B; Reider N; Covaciu CE; Cova V; Ahammer L; Eidelpes R; Unterhauser J; Platzgummer S; Tollinger M; Letschka T; Eisendle K
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1286-1292. PubMed ID: 31953891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pollen-related food allergy: cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen.
    Son DY; Scheurer S; Hoffmann A; Haustein D; Vieths S
    Eur J Nutr; 1999 Aug; 38(4):201-15. PubMed ID: 10502033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the reduced allergenic properties of the Santana apple.
    Kootstra HS; Vlieg-Boerstra BJ; Dubois AE
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):522-5. PubMed ID: 18219833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term storage on Mal d 1 content of four apple cultivars with initial low Mal d 1 content.
    Kiewning D; Schmitz-Eiberger M
    J Sci Food Agric; 2014 Mar; 94(4):798-802. PubMed ID: 24130074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Incidence of Delayed-Type Hypersensitivity Reactions to Apples Among Patients Allergic to Birch Pollen.
    Wagner A; Zielińska-Bliźniewska H; Wagner W
    Allergy Asthma Immunol Res; 2018 Jul; 10(4):420-424. PubMed ID: 29949838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
    Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
    J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional indications for the low allergenic properties of the apple cultivars Santana and Elise.
    Vlieg-Boerstra BJ; van de Weg WE; van der Heide S; Skypala I; Bures P; Ballmer-Weber BK; Hoffmann-Sommergruber K; Zauli D; Ricci G; Dubois AE
    Plant Foods Hum Nutr; 2013 Dec; 68(4):391-5. PubMed ID: 24036616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoblotting in the diagnosis of cross-reactivity in children allergic to birch.
    Cudowska B; Kaczmarski M; Restani P
    Rocz Akad Med Bialymst; 2005; 50():268-73. PubMed ID: 16358981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy.
    Khaitov M; Shilovskiy I; Valenta R; Weber M; Korneev A; Tulaeva I; Gattinger P; van Hage M; Hofer G; Konradsen JR; Keller W; Akinfenwa O; Poroshina A; Ilina N; Fedenko E; Elisyutina O; Litovkina A; Smolnikov E; Nikonova A; Rybalkin S; Aldobaev V; Smirnov V; Shershakova N; Petukhova O; Kudlay D; Shatilov A; Timofeeva A; Campana R; Udin S; Skvortsova V
    Allergy; 2024 Apr; 79(4):1001-1017. PubMed ID: 37855043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China.
    Hao GD; Zheng YW; Wang ZX; Kong XA; Song ZJ; Lai XX; Spangfort MD
    J Zhejiang Univ Sci B; 2016 May; 17(5):399-404. PubMed ID: 27143268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergy to apple cultivars among patients with birch pollinosis and oral allergy syndrome.
    Wagner A; Szwed A; Buczyłko K; Wagner W
    Ann Allergy Asthma Immunol; 2016 Oct; 117(4):399-404. PubMed ID: 27593099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of polyphenolic content on the in vitro allergenicity of old and new apple cultivars: A pilot study.
    Kschonsek J; Wiegand C; Hipler UC; Böhm V
    Nutrition; 2019 Feb; 58():30-35. PubMed ID: 30278427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study.
    Nothegger B; Reider N; Covaciu CE; Cova V; Ahammer L; Eidelpes R; Unterhauser J; Platzgummer S; Raffeiner E; Tollinger M; Letschka T; Eisendle K
    Immun Inflamm Dis; 2021 Jun; 9(2):503-511. PubMed ID: 33621436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients.
    Asero R
    Clin Exp Allergy; 1998 Nov; 28(11):1368-73. PubMed ID: 9824409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Birch pollen immunotherapy inhibits anaphylaxis to the cross-reactive apple allergen Mal d 1 in mice.
    Utsch L; Logiantara A; Wallner M; Hofer H; van Ree R; van Rijt LS
    Clin Exp Allergy; 2016 Nov; 46(11):1474-1483. PubMed ID: 27376790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization profiles in birch pollen-allergic patients with and without oral allergy syndrome to apple: lessons from multiplexed component-resolved allergy diagnosis.
    Ebo DG; Bridts CH; Verweij MM; De Knop KJ; Hagendorens MM; De Clerck LS; Stevens WJ
    Clin Exp Allergy; 2010 Feb; 40(2):339-47. PubMed ID: 19709127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
    J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells.
    Fritsch R; Bohle B; Vollmann U; Wiedermann U; Jahn-Schmid B; Krebitz M; Breiteneder H; Kraft D; Ebner C
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):679-86. PubMed ID: 9802379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.